Special considerations for the child with obesity: An Obesity Medicine Association (OMA) clinical practice statement (CPS) 2024

Suzanne Cuda, Marisa Censani, Valerie O'Hara, Jennifer Paisley, Roohi Kharofa, Rushika Conroy, Brooke Sweeney, Cristina Fernandez, Meredith L. Dreyer Gillette, Nancy T. Browne
{"title":"Special considerations for the child with obesity: An Obesity Medicine Association (OMA) clinical practice statement (CPS) 2024","authors":"Suzanne Cuda,&nbsp;Marisa Censani,&nbsp;Valerie O'Hara,&nbsp;Jennifer Paisley,&nbsp;Roohi Kharofa,&nbsp;Rushika Conroy,&nbsp;Brooke Sweeney,&nbsp;Cristina Fernandez,&nbsp;Meredith L. Dreyer Gillette,&nbsp;Nancy T. Browne","doi":"10.1016/j.obpill.2024.100113","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) details assessment and management of the child with overweight or obesity. The term “child” is defined as the child between 2 and 12 years of age. Because children are in a continual state of development during this age range, we will specify when our discussion applies to subsets within this age range. For the purposes of this CPS, we will use the following definitions: overweight in the child is a body mass index (BMI) ≥ 85th and &lt;95th percentile, obesity in the child is a BMI ≥95th percentile, and severe obesity is a BMI ≥120% of the 95th percentile.</p></div><div><h3>Methods</h3><p>The information and clinical guidance in this <span>OMA</span> Clinical Practice Statement are based on scientific evidence, supported by medical literature, and derived from the clinical perspectives of the authors.</p></div><div><h3>Results</h3><p>This OMA Clinical Practice Statement provides an overview of prevalence of disease in this population, reviews precocious puberty in the child with obesity, discusses the current and evolving landscape of the use of anti-obesity medications in children in this age range, discusses the child with obesity and special health care needs, and reviews hypothalamic obesity in the child.</p></div><div><h3>Conclusions</h3><p>This OMA Clinical Practice Statement on the child with obesity is an evidence based review of the literature and an overview of current recommendations. This CPS is intended to provide a roadmap to the improvement of the health of children with obesity, especially those with metabolic, physiological, psychological complications and/or special healthcare needs. This CPS addresses treatment recommendations and is designed to help the clinician with clinical decision making.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000159/pdfft?md5=084fe606099e8a1bea3be311f1cde0e6&pid=1-s2.0-S2667368124000159-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Pillars","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667368124000159","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) details assessment and management of the child with overweight or obesity. The term “child” is defined as the child between 2 and 12 years of age. Because children are in a continual state of development during this age range, we will specify when our discussion applies to subsets within this age range. For the purposes of this CPS, we will use the following definitions: overweight in the child is a body mass index (BMI) ≥ 85th and <95th percentile, obesity in the child is a BMI ≥95th percentile, and severe obesity is a BMI ≥120% of the 95th percentile.

Methods

The information and clinical guidance in this OMA Clinical Practice Statement are based on scientific evidence, supported by medical literature, and derived from the clinical perspectives of the authors.

Results

This OMA Clinical Practice Statement provides an overview of prevalence of disease in this population, reviews precocious puberty in the child with obesity, discusses the current and evolving landscape of the use of anti-obesity medications in children in this age range, discusses the child with obesity and special health care needs, and reviews hypothalamic obesity in the child.

Conclusions

This OMA Clinical Practice Statement on the child with obesity is an evidence based review of the literature and an overview of current recommendations. This CPS is intended to provide a roadmap to the improvement of the health of children with obesity, especially those with metabolic, physiological, psychological complications and/or special healthcare needs. This CPS addresses treatment recommendations and is designed to help the clinician with clinical decision making.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肥胖症儿童的特殊考虑因素:肥胖症医学协会(OMA)临床实践声明(CPS)2024
背景本肥胖医学协会(OMA)临床实践声明(CPS)详细介绍了对超重或肥胖儿童的评估和管理。儿童 "是指 2 到 12 岁的儿童。由于儿童在这一年龄段处于持续发育阶段,因此我们将明确说明我们的讨论何时适用于这一年龄段的子集。在本 CPS 中,我们将使用以下定义:儿童超重是指体重指数(BMI)≥ 第 85 百分位数和第 95 百分位数;儿童肥胖是指体重指数≥ 第 95 百分位数;严重肥胖是指体重指数≥ 第 95 百分位数的 120%。结果本OMA临床实践声明概述了该人群的疾病流行情况,回顾了肥胖症儿童的性早熟情况,讨论了在该年龄段儿童中使用抗肥胖药物的现状和演变情况,讨论了肥胖症儿童和特殊健康护理需求,并回顾了儿童的下丘脑肥胖症。本 CPS 旨在为改善肥胖症儿童的健康状况提供路线图,尤其是那些有代谢、生理、心理并发症和/或特殊医疗需求的儿童。本 CPS 涉及治疗建议,旨在帮助临床医生做出临床决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Efficacy of in-person versus digital enhanced lifestyle interventions in adults with overweight and obesity Effect of resveratrol supplementation on metabolic risk markers and anthropometric parameters in individuals with obesity or overweight: A systematic review and meta-analysis of randomized controlled trials Diagnosis and management of metabolic dysfunction- associated steatotic liver disease in South Asians- A clinical review Case report of a female western Indian vegetarian with obesity Retrospective review of seven patients with obesity simultaneously treated with a combination of a glucagon-like peptide-1 receptor agonist and a meal replacement product
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1